|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on April 30, 2002; DOI 10.1182/blood-2002-02-0527.
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
From the Divisions of Clinical Research and Public
Health Sciences, Fred Hutchinson Cancer Research Center; the
Departments of Biostatistics, Medicine, Pathology, Pediatrics, and
Pharmaceutics, University of Washington, and Veterans Administration
Medical Center, Seattle, WA.
A total of 109 patients (aged 6-66 years; median, 46 years)
with myelodysplastic syndrome (MDS) were treated with busulfan (BU)
targeted to plasma concentrations of 800 to 900 ng/mL plus cyclophosphamide (CY), 2 × 60 mg/kg, and hemopoietic stem cell (HSC)
transplantation from related (n = 45) or unrelated donors (n = 64). At the time of transplantation, 69 patients had less than
5% myeloblasts in the marrow, and 40 patients had more advanced disease. All but 2 evaluable patients had engraftment. The Kaplan-Meier estimates of 3-year relapse-free survival (RFS) were 56% for related and 59% for unrelated recipients. The cumulative incidences of relapse
were 16% for related and 11% for unrelated recipients. Nonrelapse
mortality (NRM) at 100 days (3 years) was 12% (28%) for related and
13% (30%) for unrelated recipients. The only factor significant for
RFS was the etiology of MDS (de novo better than treatment related;
P = .03). Factors significantly correlated with relapse
were advanced French-American-British classification (P = .002) and International Prognostic Scoring System
score (P = .009), poor-risk cytogenetics
(P = .03), and treatment-related etiology
(P = .03). None of the factors examined was statistically significant for NRM. Patient age and donor type had no significant impact on outcome. RFS tended to be superior in patients receiving transplants with peripheral blood rather than marrow stem cells. Thus,
a targeted BUCY regimen provided effective transplant conditioning for
patients with MDS receiving transplants from HLA-identical siblings or
alternative donors. Although there was still considerable nonrelapse
morbidity and mortality, the present regimen was used successfully even
in patients older than 60 years of age.
(Blood. 2002;100:1201-1207) The myelodysplastic syndromes (MDSs) are clonal
hemopoietic disorders, characterized by ineffective hemopoiesis
resulting in single or multilineage peripheral blood cytopenias,
dysplastic morphology in single or multiple lineages, and, in many
patients, clonal cytogenetic abnormalities. The French-American-British (FAB) classification has subdivided the disease into refractory anemia
(RA; < 5% marrow blasts), RA with ringed sideroblasts (RARS), RA
with excess blasts (RAEB; 5%-20% blasts), and RAEB in transformation (RAEB-T; 21%-30% blasts).1 A World Health Organization
proposal suggests that patients with more than 20% blasts should now
be considered as having acute myeloid leukemia (AML).2
Chronic myelomonocytic leukemia (CMML) was previously considered an
MDS, but has recently been reclassified as a myeloproliferative
disorder. In an attempt to improve prognostic accuracy for patients
with MDS, a team of investigators has proposed the International
Prognostic Scoring System (IPSS), which considers, in addition to the
proportion of blasts, clonal chromosomal abnormalities and the number
of peripheral blood cytopenias.3 Depending on the IPSS
score, a patient's median life expectancy may be as long as a decade or as short as a few months.
Currently, the only established therapy with curative potential for MDS
is a hemopoietic stem cell transplant (HSCT).4 Investigators generally agree that for patients with advanced disease,
particularly those of younger age, HSC transplantation is the treatment
of choice. Transplantation for less advanced disease, especially in
older patients and with the use of unrelated volunteer donors, has
remained controversial. The major reason for this controversy is the
incidence of posttransplantation nonrelapse mortality (NRM), which in
some trials has been as high as 50% to 60%.5-11
We have developed a transplant-conditioning regimen that combines oral
busulfan (BU) targeted to predetermined plasma levels in combination
with cyclophosphamide (CY). Observations in patients with chronic
myelocytic leukemia indicated that this approach was associated with
reduced toxicity and with a low probability of leukemia
relapse.12 Encouraged by those observations, we conducted
the present trial in patients with MDS. Preliminary data from this
trial suggested that NRM was reduced, and as a result, relapse-free
survival (RFS) improved compared to RFS achieved with total body
irradiation (TBI)-conditioning regimens. Here, we present a
comprehensive analysis of this trial enrolling patients with less
advanced, as well as more advanced, MDS who received HSCTs from
related or unrelated donors.
Patients
All patients had received transfusions of red blood cells, platelets,
or both. Additional therapy before referral in some patients included
administration of granulocyte colony-stimulating factor (G-CSF),
erythropoietin, or additional growth factors for variable periods of
time. Others had received androgens or glucocorticoids in the recent or
distant past. Six patients (5 with tAML and 1 with RAEB-T) received
induction-type chemotherapy (generally cytosine arabinoside combined
with daunorubicin or topotecan) before transplantation. Five achieved a
remission as defined by marrow morphology, although in 2 patients
peripheral blood cell counts had not reached normal values. One of the
6 had 10% blasts in the marrow at the time of transplantation.
Conditioning regimen
Donors Donor and transplant characteristics are summarized in Table 2. Forty-five patients received transplants from related donors (HLA-identical siblings [n = 41]; HLA-phenotypically matched relative [n = 1]; DQB1-mismatched relative [n = 1]; DRB1-mismatched relative [n = 1]; and 1 from a syngeneic donor), and 64 from volunteer unrelated donors (HLA-matched by intermediate- or high-resolution typing in 53 cases; mismatched for one HLA-A antigen in 4, one HLA-B antigen in 1, one DR antigen [allele] in 1, one HLA-A plus one HLA-B antigen in 3, and one HLA-B plus one HLA-C antigen in 2 cases).17,18
Source of stem cells The source of stem cells was marrow in 81 patients and peripheral blood after G-CSF mobilization in 28 patients (19 HLA-identical siblings, 6 HLA-identical unrelated donors, and 3 HLA-nonidentical donors).Graft-versus-host disease prophylaxis Prophylaxis for acute graft-versus-host disease (GVHD) consisted of methotrexate (MTX) and cyclosporine (CSP) in 97 patients, CSP plus mycophenolate mofetil (MMF) in 6, and MTX and FK506 in 5 patients.19,20 One patient had a syngeneic donor and received no GVHD prophylaxis. Adjustments for MTX, CSP, MMF, and FK506 were made if deemed clinically necessary. Acute and chronic GVHD were diagnosed and graded using established criteria.21,22 Standard therapy for acute GVHD consisted of methylprednisolone. Steroid-refractory GVHD was treated according to various protocols involving the use of antithymocyte globulin, monoclonal antibodies, rapamycin (sirolimus), or MMF.23-25Engraftment and rejection The day of engraftment was defined as the first of 3 consecutive days on which the neutrophil count exceeded 0.5 × 109/L.17 Evidence of graft rejection was sought when the absolute neutrophil count (ANC) failed to reach 0.5 × 109/L, when the ANC declined after initial recovery, and when relapse was diagnosed. Patients who died before day 28 were considered nonevaluable for engraftment. When the donor and patient were of different gender, fluorescence in situ hybridization with Y or X chromosome-specific probes was performed on bone marrow and peripheral blood mononuclear cells (PBMCs).26,27 When patient and donor were of the same gender, DNA from marrow and PBMCs was amplified for several variable number tandem repeat loci for identification of informative host and donor markers.28Relapse All patients were scheduled to have marrow samples examined morphologically and by cytogenetic and flow cytometric analyses on days 28 and 84 after transplantation, and then annually or as clinically indicated. Relapse was defined morphologically as the detection of metaphases in the marrow that showed the same clonal marker(s) identified before transplantation, or as the reemergence of blasts or aberrant precursors identified by flow cytometry.29Infection Blood samples were examined weekly for evidence of cytomegalovirus (CMV) antigenemia. Interstitial pneumonia was diagnosed on the basis of radiographic findings, by use of culture, histologic, or histochemical analysis of bronchoalveolar lavage fluid, open lung biopsy, or at autopsy. Strategies to prevent infectious diseases included the prophylactic use of systemic antibiotics, fluconazole, acyclovir, and ganciclovir. All CMV-seronegative patients received CMV blood products. Acyclovir prophylaxis was given to
all patients who were seropositive for herpes simplex or herpes zoster
virus. Ganciclovir was given to all CMV-seropositive recipients at
engraftment or at the first documentation of
antigenemia.30
Causes of death Deaths that occurred after posttransplantation relapse were categorized as due to relapse regardless of the proximate causes; deaths in the absence of relapse were categorized as NRM. Infection was considered the cause of death when a bacterial, viral, or fungal infection other than interstitial pneumonia was the proximate cause of death in patients who had not had relapse. Infections were further categorized according to whether or not they were associated with GVHD and with organ failure. Multiorgan failure was considered the cause of death if decompensation occurred in at least 2 organ systems (eg, liver and kidneys or liver and lungs) and could not be attributed to GVHD or infection alone.Statistical analysis The probabilities of RFS were estimated using the Kaplan-Meier method.31 The incidences of relapse and NRM were expressed in terms of cumulative incidence (CI).32 Cox regression was used to analyze risk factors related to the hazard rates for these outcomes. In these analyses, relapse and NRM were considered competing events. The time to these outcomes was censored at the time of the competing event. Multivariate models were constructed by a forward selection procedure. At each step, the most significant factor at a level of at least 0.05 was added. Multivariate P values refer to the significance of the factor after adjusting for other factors in the final multivariate model. All P values are based on likelihood ratio statistics from Cox regression models and are 2-sided. Results were analyzed as of June 30, 2001.
Conditioning The target range steady-state plasma level for BU was 800 to 900 ng/mL. The actual BU_Css levels reached were 635 to 1140 ng/mL (median, 883 ng/mL) with 65 patients (60%) in the prescribed target range. Although 13% of patients achieved this level with the prescribed doses, 78% required BU dose reductions, and 9% required increments. The actual total dose of BU administered ranged from 9.6 to 20.2 mg/kg (mean, 14.3 mg/kg). The doses in 7 patients younger than 10 years were not significantly different from the remainder of the study cohort. All patients received the prescribed dose of CY, 2 × 60 mg/kg.Engraftment Five patients died before day 28 and were not considered evaluable for engraftment. A total of 104 patients achieved engraftment, as determined by an ANC of 0.5 × 109/L at 10 to 30 days (median, 19 days), and 90 reached platelet counts of more than 20 × 109/L at 7 to 137 days (median, 21 days) after transplantation. Two patients showed recovery of host cells, and both died, one after 2 additional attempts at transplantation. Engraftment was sustained in the remaining 102 patients.GVHD Acute GVHD of grades II to IV developed in 78 patients for CIs 64% among patients with HLA-identical sibling donors, 68% among patients with HLA-matched unrelated donors, and 100% among patients with HLA-nonidentical related or unrelated donors. The incidence of GVHD of grades III to IV was 7% after HLA-identical sibling transplants, 19% after matched unrelated transplants, and 29% after HLA-nonidentical transplants. In all but one patient, GVHD developed before day 30.Chronic GVHD occurred in 47% of patients, and incidence rates were similar with related and unrelated donors, and with HLA-identical and -nonidentical recipients. RFS Currently, 64 patients are surviving, 62 in continued complete remission. Overall relapse incidence, RFS, and NRM for HLA-matched donor transplants are summarized in Table 3. The probability of 3-year RFS was 56% with HLA-identical sibling donors, 59% with HLA-matched unrelated donors, and 27% with HLA-mismatched donors (Figure 1). Among recipients of HLA-identical sibling transplants, RFS at 3 years was 68% for patients with RA/RARS, 45% for patients with RAEB, and 33% for patients with more advanced disease. Corresponding figures for patients with matched unrelated donors were 70%, 40%, and 17%, respectively.
Relapse-free survival by IPSS category is shown in Figure
2A. The 3-year RFS was 80% among
patients in the low-risk group (IPSS score 0), and progressively
decreased with increasing scores to 29% among patients with an IPSS
score higher than 2.
Relapse Thirteen patients had recurrent or progressive disease, reaching a cumulative incidence of 14% at 3 years, and 11 of these have died (Table 4). The 3-year incidence of relapse was strongly correlated with cytogenetic findings (9%, 13%, and 26%, for good, intermediate, and poor risk, respectively), with FAB category (5%, 34%, and 32% for RA/RARS, RAEB, and RAEB-T/tAML, respectively), and IPSS score (0%, 6%, 29%, and 42% for low, intermediate-1, intermediate-2, and high risk, respectively, Figure 2B).
NRM The NRM rate among all patients was 16% by day 100, and 31% by 3 years, 12% and 28%, respectively, for HLA-identical sibling transplants, 13% and 30%, respectively, for matched unrelated donor transplants, and 36% and 52%, respectively, for recipients of HLA-nonidentical transplants.Forty-five patients have died. Causes of death are summarized in Table 4. The most frequent causes of death, in addition to relapse, were organ failure, in particular veno-occlusive disease of the liver, GVHD with bacterial infections or disseminated aspergillosis, and pneumonia/idiopathic pneumonitis syndrome. Effect of source of hemopoietic stem cells Among 28 patients receiving PBSC transplants, the 3-year RFS was 68%, compared to 48% for patients receiving marrow transplants. Differences were observed in all MDS categories (Figure 3; RA/RARS, 83% versus 61%; advanced MDS, 63% versus 32%; IPSS score 1, 82% versus 61%; IPSS score > 1, 80% versus 38%). These differences were not affected by year of
transplantation.
Statistical analyses Results of univariate analysis are shown in Table 5. The most significant risk factors for relapse were the etiology of MDS (hazard ratio for prior chemotherapy or radiotherapy 5.4, and for prior hematologic diagnosis, 0.8; as compared to de novo MDS; P = .03), cytogenetic risk group (hazard ratio 2.1 for intermediate risk, and 5.2 for high risk as compared to good risk; P = .03), the FAB category (hazard ratio 8.5 for RAEB, and 8.6 for RAEB-T/tAML, as compared to RA; P = .002), and the IPSS score (P = .002; if the IPSS score was considered a continuous variable; Figure 2B). For NRM, none of the pretransplantation risk factors had a significant impact. However, NRM was higher in patients who developed acute GVHD grades II to IV (P = .006). For RFS, the etiology of MDS was significant (hazard ratio for prior chemotherapy or radiotherapy 2.8, and for prior hematologic disorder 1.3, relative to de novo MDS; P = .03); and IPSS score, if analyzed as a continuous variable (P = .04; Figure 2A). FAB category (P = .08) showed a trend for significance.
In multivariate analysis, after adjusting for etiology of MDS, no other factors, including the source of hemopoietic stem cells and patient age, were significantly associated with RFS. Similarly, no other factors were significantly associated with relapse after adjusting for either IPSS score or FAB classification.
This study shows that targeted BU plus CY provided effective conditioning for patients with MDS before HSC transplantation from related and unrelated donors. Outcomes with HLA-identical related and unrelated donors were similar. Engraftment was achieved in all but 2 patients, and early treatment-related mortality was low. The strongest predictors for relapse were FAB and IPSS classifications, and this effect on relapse was reflected in RFS. Patients with de novo MDS or MDS developing from pre-existing hematologic disorders fared better than those with therapy-related MDS. Although the BUCY regimen was originally designed for patients with RA/RARS, this trial showed that patients with more advanced/high-risk disease could undergo successful transplantation with this regimen, in agreement with earlier reports by O'Donnell et al5 and by Ratanatharathorn et al.6 In fact, RFS among patients with RAEB and RAEB-T in the present study was comparable or superior to that reported with a more intensive regimen of BU plus TBI.10 Although the relapse incidence in patients with more advanced MDS in the present study was slightly higher than reported after BU plus TBI conditioning,10 NRM was substantially lower (12%-15% at 100 days). As a result, 3-year RFS among patients with RA/RARS was 68% for HLA-matched related and 70% for unrelated transplant recipients, whereas for patients with more advanced disease (RAEB and RAEB-T/tAML), the figures were 45% and 33% for related, and 40% and 17% for unrelated transplants, respectively. Results in the small group of patients receiving transplants from HLA-nonidentical related or unrelated donors (overall RFS 27%) were similar to those reported by other investigators.33 The present data with HLA-identical transplants compare favorably with results reported recently by the European Group for Blood and Marrow Transplantation showing a 3-year RFS of 36% for patients with HLA-identical sibling donors.8,34 That study showed a high incidence of treatment-related mortality, similar to our past experience with high-dose TBI regimens.10,11,35 In agreement with previous reports, the cumulative incidence of posttransplantation relapse in the present study was twice as high in patients with poor-risk cytogenetics than in the remaining cohort.7,36 Our results indicate that the impact of cytogenetic abnormalities was of the same order of magnitude as an increase in marrow blasts. Thus, future trials, similar to studies in AML, should consider the marrow karyotype as well as the blast count in the study design. The role of pretransplantation "debulking" in patients with MDS is not well defined. Although some reports show a benefit as determined by improved posttransplantation RFS,37 other studies fail to show such an advantage, apparently due to increases in transplant-related toxicity.38 In the present study, the cumulative overall incidence of relapse was 16% for related and 11% for unrelated transplant recipients, respectively. Considering this low relapse incidence, it appears unlikely that pretransplantation debulking or induction chemotherapy would benefit a large proportion among all patients with MDS. A recent cooperative European study of MDS showed a 4-year RFS rate of 31% among patients with HLA-identical sibling donors, when the transplantation was done during complete remission after induction chemotherapy.34 This compares to 3-year RFS rates in the present study of 45% and 33% for patients with RAEB and RAEB-T/tAML, respectively, who had HLA-identical sibling donors, when the transplantation was done without preceding induction therapy. Whether there are subgroups of patients at high risk for relapse who might derive an advantage from pretransplantation chemotherapy or whether debulking therapy followed by reduced-intensity conditioning regimens might be advantageous, remains to be determined. In the current trial, over the course of 3 years, approximately one third of patients died from nonrelapse causes, such as organ failure, GVHD, and infections, especially with fungal organisms. The high frequencies of infections and organ failure are consistent with previous reports,8,10,11,34 although the causes are not clear. In part, complications may be related to the disease course before transplantation, including colonization with infectious organisms, and side effects of prolonged transfusion support. In contrast to several previous reports, the present study did not identify disease duration as a risk factor for outcome.14,35 Conceivably, the adjustments of BU doses to reach a predetermined plasma target range, which was the unique feature of the present trial, improved the tolerability of the regimen and thereby reduced NRM as suggested in previous reports.12,13 Because regimen-related toxicity has generally been high in older patients, reduction in conditioning-related toxicity may also be a major reason why patient age did not have a significant impact on outcome in this study. Although the incidence of relapse tended to increase with age, NRM did not, and RFS among 23 patients older than 55 years of age (8 of these were 60 years or older) was similar to that in younger patients. These data confirm an earlier preliminary report from our center13 and are in agreement with a recent study of more than 500 patients with MDS who had unrelated donors.39 Although the overall incidence of acute GVHD was high, it was not different from that in patients with acute leukemia undergoing transplantation in Seattle, and acute GVHD of grades III to IV was infrequent (7% and 19% for matched related and unrelated transplants, respectively). Further, there was no significant difference in the incidence of GVHD between related and unrelated recipients of HLA-matched transplants, supporting the findings from other studies that show that with donor selection based on intermediate- or high-resolution HLA typing, results with unrelated donors are comparable to those with HLA-identical sibling donors.18 However, in agreement with previous studies, patients who developed acute GVHD experienced significantly higher transplant-related mortality and had a lower RFS. Determination of the best source of hemopoietic stem cells for allogeneic transplants has remained a major focus of transplantation research.40-43 Our protocol originally prescribed the use of marrow. With increasing experience with the use of PBSCs, however, and because of frequent patient requests, the protocol was modified to allow the use of PBSCs. Differences in RFS in favor of PBSCs were observed in all subgroups of patients. Although these differences were not significant, the data suggest an advantage for PBSCs in transplantation for patients with MDS as observed for other disease groups.41-43 Thus, conditioning with targeted BUCY was effective in preparing patients with MDS for transplantation from related and unrelated donors. Relapse rates were similar to those observed with high-dose TBI regimens, whereas the incidence of treatment-related mortality was lower, and as a result, RFS was improved. FAB and IPSS classifications showed strong correlations with posttransplantation relapse. GVHD remained a problem, and novel preventive regimens deserve to be tested in patients with MDS. Although the present study did not address the feasibility of autologous transplantation in patients with MDS, the observations that recipients of unrelated donor transplants did as well as patients receiving transplants from HLA-identical siblings suggest that allogeneic transplantation should be offered more widely to patients with MDS. The fact that patient age, spanning 6 decades, was not a significant risk factor for RFS further suggests such a conclusion. Whether results as obtained with the present regimen of targeted BUCY can be improved with the use of modified preparative regimens aimed at further reducing NRM remains to be determined.
We thank Amy Mellon, Mary Beauchamp, Elizabeth Soll and Christine Kane for maintaining the patient database, Kate Rupert for help with cytogenetics, Bonnie Larson and Helen Crawford for manuscript preparation.
Submitted February 20, 2002; accepted April 4, 2002.
Prepublished online as Blood First Edition Paper, April 30, 2002; DOI 10.1182/blood-2002-02-0527.
Supported in part by grants HL36444, CA18029, CA18221, CA15704, and CA87948 from the National Institutes of Health, Bethesda, MD. E.H.W. is also supported by a Lilly Clinical Investigator Award from the Damon Runyon Cancer Research Foundation.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: H. Joachim Deeg, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1-100, PO Box 19024, Seattle, WA 98109; e-mail: jdeeg{at}fhcrc.org.
1. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189-199[Medline] [Order article via Infotrieve].
2.
Harris NL, Jaffe ES, Diebold J, et al.
World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting, Airlie House, Virginia, November 1997.
J Clin Oncol.
1999;17:3835-3849
3.
Greenberg P, Cox C, LeBeau MM, et al.
International scoring system for evaluating prognosis in myelodysplastic syndromes (published erratum appears in Blood. 1998;91:1100).
Blood.
1997;89:2079-2088 4. Deeg HJ, Appelbaum FR. Hematopoietic stem cell transplantation in patients with myelodysplastic syndrome [review]. Leuk Res. 2000;24:653-663[CrossRef][Medline] [Order article via Infotrieve]. 5. O'Donnell MR, Long GD, Parker PM, et al. Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. J Clin Oncol. 1995;13:2973-2979[Abstract].
6.
Ratanatharathorn V, Karanes C, Uberti J, et al.
Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes.
Blood.
1993;81:2194-2199
7.
Nevill TJ, Fung HC, Shepherd JD, et al.
Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation.
Blood.
1998;92:1910-1917 8. De Witte T, Hermans J, Vossen J, et al. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol. 2000;110:620-630[CrossRef][Medline] [Order article via Infotrieve]. 9. Gassmann W, Schmitz N, Loffler H, De Witte T. Intensive chemotherapy and bone marrow transplantation for myelodysplastic syndromes. Semin Hematol. 1996;33:196-205[Medline] [Order article via Infotrieve]. 10. Jurado M, Deeg HJ, Storer B, et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable non-relapse mortality. Biol Blood Marrow Transplant. 2002;8:161-169[CrossRef][Medline] [Order article via Infotrieve]. 11. Anderson JE, Appelbaum FR, Schoch G, et al. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol. 1996;14:220-226[Abstract].
12.
Slattery JT, Clift RA, Buckner CD, et al.
Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation.
Blood.
1997;89:3055-3060
13.
Deeg HJ, Shulman HM, Anderson JE, et al.
Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age.
Blood.
2000;95:1188-1194 14. Anderson JE, Appelbaum FR, Barnett T, Chauncey TR, Flowers M, Storb R. Relapse after allogeneic bone marrow transplantation (BMT) for myelodysplasia (MDS) subtype refractory anemia (RA) is increased by shielding lungs and liver during irradiation [abstract]. Blood. 1998;92(suppl 1):659a. 15. Slattery JT, Sanders JE, Buckner CD, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant. 1995;16:31-42[Medline] [Order article via Infotrieve]. 16. Slattery JT, Risler LJ. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit. 1998;20:543-549[CrossRef][Medline] [Order article via Infotrieve].
17.
Petersdorf EW, Longton GM, Anasetti C, et al.
Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors.
Blood.
1997;89:1818-1823
18.
Petersdorf EW, Hansen JA, Martin PJ, et al.
Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation.
N Engl J Med.
2001;345:1794-1800 19. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314:729-735[Abstract].
20.
Ratanatharathorn V, Nash RA, Przepiorka D, et al.
Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host-disease prophylaxis after HLA-identical sibling bone marrow transplantation.
Blood.
1998;92:2303-2314 21. Martin P, Nash R, Sanders J, et al. Reproducibility in retrospective grading of acute graft-versus-host disease after allogeneic marrow transplantation. Bone Marrow Transplant. 1998;21:273-279[CrossRef][Medline] [Order article via Infotrieve]. 22. Sullivan KM. Graft-versus-host-disease. In: Thomas ED,Blume KG,Forman SJ, eds. Hematopoietic Cell Transplantation. 2nd ed. Boston, MA: Blackwell Science; 1999:515-536. 23. Nash RA, Furlong T, Storb R, et al. Mycophenolate mofetil (MMF) as salvage treatment for graft-versus-host-disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT): safety analysis [abstract]. Blood. 1997;90(suppl 1):105a. 24. Benito AI, Furlong T, Martin PJ, et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation. 2001;72:1924-1929[CrossRef][Medline] [Order article via Infotrieve].
25.
Carpenter PA, Appelbaum FR, Corey L, et al.
A humanized non-FCR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease.
Blood.
2002;99:2712-2719
26.
Durnam DM, Anders KR, Fisher L, O'Quigley JO, Bryant EM, Thomas ED.
Analysis of the origin of marrow cells in bone marrow transplant recipients using a Y-chromosome-specific in situ hybridization assay.
Blood.
1989;74:2220-2226 27. Shulman HM, Wells D, Gooley T, Myerson D, Bryant E, Loken MR. The biologic significance of rare peripheral blasts after hematopoietic cell transplantation is predicted by multidimensional flow cytometry. Am J Clin Pathol. 1999;112:513-523[Medline] [Order article via Infotrieve].
28.
Scharf SJ, Smith AG, Hansen JA, McFarland C, Erlich HA.
Quantitative determination of bone marrow transplant engraftment using fluorescent polymerase chain reaction primers for human identity markers.
Blood.
1995;85:1954-1963
29.
Sievers EL, Lange BJ, Buckley JD, et al.
Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry.
J Natl Cancer Inst.
1996;88:1483-1488 30. Boeckh M, Stevens-Ayers T, Bowden RA. Cytomegalovirus pp65 antigenemia after autologous marrow and peripheral blood stem cell transplantation. J Infect Dis. 1996;174:907-912[Medline] [Order article via Infotrieve]. 31. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481[CrossRef]. 32. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695-706[CrossRef][Medline] [Order article via Infotrieve]. 33. De Witte T, Pikkemaat F, Hermans J, et al. Genotypically nonidentical related donors for transplantation of patients with myelodysplastic syndromes: comparison with unrelated donor transplantation and autologous stem cell transplantation. Leukemia. 2001;15:1878-1884[Medline] [Order article via Infotrieve].
34.
De Witte T, Suciu S, Verhoef G, et al.
Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS.
Blood.
2001;98:2326-2331
35.
Anderson JE, Appelbaum FR, Schoch G, et al.
Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors.
Blood.
1996;87:51-58 36. Appelbaum FR, Anderson J. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia. 1998;12(suppl 1):S25-S29.
37.
Yakoub-Agha I, de La Salomière P, Ribaud P, et al.
Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French Society of bone marrow transplantation.
J Clin Oncol.
2000;18:963-971
38.
Anderson JE, Gooley TA, Schoch G, et al.
Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy.
Blood.
1997;89:2578-2585
39.
Castro-Malaspina H, Harris RE, Gajewski J, et al.
Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program.
Blood.
2002;99:1943-1951 40. Bensinger WI, Deeg HJ. Blood or marrow? [commentary]. Lancet. 2000;355:1199-1200[CrossRef][Medline] [Order article via Infotrieve].
41.
Bensinger WI, Martin PJ, Storer B, et al.
Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers.
N Engl J Med.
2001;344:175-181 42. Schmitz N, Beksac M, Hasenclever D, et al. A randomised study from the European Group for Blood and Marrow Transplantation comparing allogeneic transplantation of filgrastim-mobilised peripheral blood progenitor cells with bone marrow transplantation in 350 patients (pts) with leukemia [abstract]. Blood. 2000;96 (pt 1):481a. 43. Powles R, Mehta J, Kulkarni S, et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet. 2000;355:1231-1237[CrossRef][Medline] [Order article via Infotrieve].
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top
Abstract
Introduction
